Quantbot Technologies LP Purchases Shares of 13,044 Exelixis, Inc. $EXEL

Quantbot Technologies LP purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,044 shares of the biotechnology company’s stock, valued at approximately $539,000.

A number of other institutional investors have also modified their holdings of EXEL. TriaGen Wealth Management LLC purchased a new position in Exelixis during the third quarter valued at approximately $2,024,000. BridgePort Financial Solutions LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth approximately $517,000. Candriam S.C.A. increased its holdings in shares of Exelixis by 18.4% during the 3rd quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock valued at $28,749,000 after purchasing an additional 108,367 shares in the last quarter. Allianz Asset Management GmbH lifted its stake in shares of Exelixis by 153.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock valued at $101,720,000 after purchasing an additional 1,490,520 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in Exelixis during the second quarter worth $321,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of recent analyst reports. Wolfe Research began coverage on shares of Exelixis in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Stifel Nicolaus lifted their price target on Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada reduced their price target on Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a report on Monday, March 2nd. Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Finally, Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Ten equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $46.94.

Insider Transactions at Exelixis

In related news, Director Jack L. Wyszomierski sold 99,574 shares of Exelixis stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total value of $4,382,251.74. Following the completion of the sale, the director owned 279,942 shares in the company, valued at approximately $12,320,247.42. The trade was a 26.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bob Oliver sold 30,250 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the sale, the director directly owned 21,120 shares in the company, valued at $925,267.20. This represents a 58.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 362,849 shares of company stock worth $15,917,463 over the last three months. Insiders own 2.82% of the company’s stock.

Exelixis Stock Up 0.6%

NASDAQ EXEL opened at $41.54 on Monday. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62. The business has a 50 day moving average price of $43.57 and a two-hundred day moving average price of $41.60. The stock has a market cap of $10.79 billion, a PE ratio of 15.00, a P/E/G ratio of 0.93 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.55 earnings per share. Sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.